Skip to content
OpenCapital
Get started

Bausch Health Companies BHC Increase (Decrease) in Accounts Receivable

Increase (Decrease) in Accounts Receivable at other companies

Henry Schein logo
Henry ScheinHSIC
$69M-6.8%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
——

Other financials

Income statement

See full
Revenue$2.5B+11.7%
Operating income-$950.0M-444%
Net income-$1.4B-2,353%
EPS (diluted)-$3.82-2,287%

Balance sheet

See full
Cash & equivalents$1.3B+13.4%
Total debt$20.8B-3.5%
Total equity-$2.1B-74.0%
Total assets$24.5B-7.3%

Cash flow

See full
Operating cash flow$230.0M+9.0%
CapEx$109.0M-5.2%
Free cash flow$121.0M+26.0%

Valuation

See full
Market cap$1.86B-15.9%

Profitability

See full
Gross margin71.4%—
Operating margin5.6%-10.3pp
Net margin-1.9%-0.9pp
FCF margin9.8%-2.8pp

Returns & leverage

See full
Return on equity-70.1%—
Debt / equity45.2×—
Current ratio1.3×0.0×

Where this comes from

Reported directly by Bausch Health Companies in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: Bausch Health Companies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch Health Companies's increase (decrease) in accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bausch Health Companies's increase (decrease) in accounts receivable?
Bausch Health Companies (BHC) reported increase (decrease) in accounts receivable of -$148M in Q1 2026.
How has Bausch Health Companies's increase (decrease) in accounts receivable changed year-over-year?
Bausch Health Companies's increase (decrease) in accounts receivable decreased by 34.5% year-over-year, from -$110M to -$148M.
What is the long-term trend for Bausch Health Companies's increase (decrease) in accounts receivable?
Over 2 years (2021 to 2023), Bausch Health Companies's increase (decrease) in accounts receivable has grown at a -7.7% compound annual growth rate (CAGR), from $229M to $195M.